#

Ulcerative Colitis (IQVIA)

  • Compensation to be determined
  • 13 visits (enrollment open)
#

18+ Years

#
Male or Female
#
Smoker & Non-Smoker

Description

A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.

Is this not what you are looking for?
Check out our other studies.

Related Studies

#

Depression (ALTO)

  • Compensation to be determined
  • The total number of visits is 12 with 5 visits in clinic and 7 remote visits
#
Between 18 - 65 Years

#
Male or Female
#
Smoker & Non-Smoker
#

Ulcerative Colitis (IQVIA)

  • Compensation to be determined
  • clinic visits 10
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

Small Cell Lung Cancer

  • Compensation to be determined
  • Clinical visits 24
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
© 2024 Access Research Institute. All Rights Reserved